Kwang Dong Pharmaceutical Co., Ltd. (009290.KS)
KRW 5500.0
(0.36%)
KRW 5500.0
(0.36%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 235.64 Billion KRW | 70.75% |
| 2022 | 138 Billion KRW | 4.51% |
| 2021 | 132.04 Billion KRW | 20.37% |
| 2020 | 109.7 Billion KRW | -2.18% |
| 2019 | 112.14 Billion KRW | 10.35% |
| 2018 | 101.62 Billion KRW | -7.83% |
| 2017 | 110.26 Billion KRW | 10.37% |
| 2016 | 99.9 Billion KRW | -0.7% |
| 2015 | 100.6 Billion KRW | 54.33% |
| 2014 | 65.18 Billion KRW | 13.92% |
| 2013 | 57.22 Billion KRW | -16.47% |
| 2012 | 68.51 Billion KRW | 187.86% |
| 2011 | 23.8 Billion KRW | -2.69% |
| 2010 | 24.45 Billion KRW | -7.51% |
| 2009 | 26.44 Billion KRW | -4.65% |
| 2008 | 27.73 Billion KRW | -4.32% |
| 2007 | 28.98 Billion KRW | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 278.37 Billion KRW | 11.3% |
| 2024 Q1 | 250.1 Billion KRW | 6.14% |
| 2023 Q2 | 192.06 Billion KRW | 11.82% |
| 2023 Q3 | 191.53 Billion KRW | -0.28% |
| 2023 Q4 | 235.64 Billion KRW | 23.03% |
| 2023 FY | 235.64 Billion KRW | 70.75% |
| 2023 Q1 | 171.76 Billion KRW | 24.47% |
| 2022 Q4 | 138 Billion KRW | -3.2% |
| 2022 Q3 | 142.56 Billion KRW | -1.71% |
| 2022 Q2 | 145.03 Billion KRW | 23.54% |
| 2022 FY | 138 Billion KRW | 4.51% |
| 2022 Q1 | 117.39 Billion KRW | -11.09% |
| 2021 Q2 | 131.47 Billion KRW | 10.06% |
| 2021 Q3 | 131.17 Billion KRW | -0.23% |
| 2021 FY | 132.04 Billion KRW | 20.37% |
| 2021 Q1 | 119.45 Billion KRW | 8.89% |
| 2021 Q4 | 132.04 Billion KRW | 0.66% |
| 2020 Q3 | 110.15 Billion KRW | -5.76% |
| 2020 Q4 | 109.7 Billion KRW | -0.41% |
| 2020 Q2 | 116.89 Billion KRW | 7.48% |
| 2020 FY | 109.7 Billion KRW | -2.18% |
| 2020 Q1 | 108.75 Billion KRW | -3.02% |
| 2019 Q3 | 113.31 Billion KRW | 4.37% |
| 2019 Q1 | 108.29 Billion KRW | 6.56% |
| 2019 FY | 112.14 Billion KRW | 10.35% |
| 2019 Q2 | 108.56 Billion KRW | 0.25% |
| 2019 Q4 | 112.14 Billion KRW | -1.03% |
| 2018 Q1 | 100.23 Billion KRW | -9.1% |
| 2018 Q3 | 103.96 Billion KRW | -1.65% |
| 2018 FY | 101.62 Billion KRW | -7.83% |
| 2018 Q4 | 101.62 Billion KRW | -2.25% |
| 2018 Q2 | 105.71 Billion KRW | 5.47% |
| 2017 FY | 110.26 Billion KRW | 10.37% |
| 2017 Q2 | 103.92 Billion KRW | 4.61% |
| 2017 Q4 | 110.26 Billion KRW | -3.3% |
| 2017 Q3 | 114.02 Billion KRW | 9.71% |
| 2017 Q1 | 99.34 Billion KRW | -0.56% |
| 2016 Q1 | 101.06 Billion KRW | 0.45% |
| 2016 Q2 | 102.57 Billion KRW | 1.5% |
| 2016 Q3 | 101.74 Billion KRW | -0.81% |
| 2016 Q4 | 99.9 Billion KRW | -1.81% |
| 2016 FY | 99.9 Billion KRW | -0.7% |
| 2015 Q1 | 104.88 Billion KRW | 60.89% |
| 2015 Q4 | 100.6 Billion KRW | -0.97% |
| 2015 Q3 | 101.59 Billion KRW | 12.17% |
| 2015 FY | 100.6 Billion KRW | 54.33% |
| 2015 Q2 | 90.57 Billion KRW | -13.64% |
| 2014 Q3 | 63.02 Billion KRW | -0.59% |
| 2014 Q2 | 63.4 Billion KRW | 10.98% |
| 2014 FY | 65.18 Billion KRW | 13.92% |
| 2014 Q4 | 65.18 Billion KRW | 3.43% |
| 2014 Q1 | 57.12 Billion KRW | -0.17% |
| 2013 Q4 | 57.22 Billion KRW | 3.13% |
| 2013 Q2 | 55.83 Billion KRW | -18.14% |
| 2013 Q1 | 68.21 Billion KRW | -0.43% |
| 2013 FY | 57.22 Billion KRW | -16.47% |
| 2013 Q3 | 55.48 Billion KRW | -0.63% |
| 2012 Q1 | 1.05 Billion KRW | 0.0% |
| 2012 FY | 68.51 Billion KRW | 187.86% |
| 2012 Q4 | 68.51 Billion KRW | 0.0% |
| 2011 FY | 23.8 Billion KRW | -2.69% |
| 2011 Q3 | 24.15 Billion KRW | -1.43% |
| 2011 Q2 | 24.5 Billion KRW | 2.73% |
| 2011 Q1 | 23.85 Billion KRW | -2.49% |
| 2010 Q4 | 24.45 Billion KRW | -2.75% |
| 2010 Q3 | 25.14 Billion KRW | 1.0% |
| 2010 FY | 24.45 Billion KRW | -7.51% |
| 2010 Q1 | 25.64 Billion KRW | -3.03% |
| 2010 Q2 | 24.9 Billion KRW | -2.9% |
| 2009 Q1 | 28.62 Billion KRW | 3.23% |
| 2009 FY | 26.44 Billion KRW | -4.65% |
| 2009 Q4 | 26.44 Billion KRW | -3.24% |
| 2009 Q3 | 27.33 Billion KRW | -6.1% |
| 2009 Q2 | 29.1 Billion KRW | 1.67% |
| 2008 Q1 | 19.11 Billion KRW | -34.07% |
| 2008 Q2 | 27.39 Billion KRW | 43.35% |
| 2008 Q3 | 27.65 Billion KRW | 0.93% |
| 2008 Q4 | 27.73 Billion KRW | 0.3% |
| 2008 FY | 27.73 Billion KRW | -4.32% |
| 2007 Q1 | 26.69 Billion KRW | 0.0% |
| 2007 FY | 28.98 Billion KRW | 0.0% |
| 2007 Q3 | 29.5 Billion KRW | 3.62% |
| 2007 Q2 | 28.47 Billion KRW | 6.67% |
| 2007 Q4 | 28.98 Billion KRW | -1.77% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -497.966% |
| Dong-A Socio Holdings Co., Ltd. | 691.88 Billion KRW | 65.942% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | -176.705% |
| Ildong Pharmaceutical Co., Ltd. | 217.84 Billion KRW | -8.171% |
| Ildong Holdings Co., Ltd. | 382.06 Billion KRW | 38.324% |
| Hana Pharm Co., Ltd. | 26.53 Billion KRW | -788.105% |
| Kukje Pharma Co., Ltd. | 30.66 Billion KRW | -668.511% |
| Yuhan Corporation | 230.07 Billion KRW | -2.421% |
| Dong-A ST Co., Ltd. | 406.7 Billion KRW | 42.061% |
| SAMSUNG PHARM. Co., LTD. | 595.48 Million KRW | -39471.285% |
| Hanall Biopharma Co.,Ltd | 1.29 Billion KRW | -18159.275% |
| Dong Sung Bio Pharm.Co.,Ltd. | 43.27 Billion KRW | -444.548% |
| MYUNGMOON Pharm co.,Ltd | 90.48 Billion KRW | -160.428% |
| Samjin Pharmaceuticals Co., Ltd. | 118.63 Billion KRW | -98.622% |
| CKD Bio Corp. | 146.92 Billion KRW | -60.38% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -497.966% |
| REYON Pharmaceutical Co., Ltd. | 225.05 Billion KRW | -4.704% |
| Aprogen pharmaceuticals,Inc. | 180.99 Billion KRW | -30.191% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | -38.384% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | -410.583% |
| Hyundai Pharmaceutical Co., Ltd. | 39.2 Billion KRW | -501.051% |
| Yungjin Pharm. Co., Ltd. | 66.88 Billion KRW | -252.324% |
| HANDOK Inc. | 300.01 Billion KRW | 21.456% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -497.966% |
| Daewoong pharmaceutical Co.,Ltd | 469.68 Billion KRW | 49.83% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | -38.384% |
| Yuhan Corporation | 230.07 Billion KRW | -2.421% |
| Jeil Pharma Holdings Inc | 173.03 Billion KRW | -36.185% |
| Hanmi Pharm. Co., Ltd. | 572.86 Billion KRW | 58.866% |
| Chong Kun Dang Pharmaceutical Corp. | 219.76 Billion KRW | -7.225% |
| Suheung Co., Ltd. | 467.85 Billion KRW | 49.634% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | -38.384% |
| Chong Kun Dang Holdings Corp. | 468.03 Billion KRW | 49.653% |
| Ilsung Pharmaceuticals Co., Ltd. | 238.12 Million KRW | -98856.588% |
| JW Holdings Corporation | 554.58 Billion KRW | 57.51% |
| Samil Pharmaceutical Co.,Ltd | 175.87 Billion KRW | -33.979% |
| Jeil Pharmaceutical Co.,Ltd | 84.96 Billion KRW | -177.337% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | -410.583% |
| Daewon Pharmaceutical Co., Ltd. | 146.04 Billion KRW | -61.343% |
| Korea United Pharm Inc. | 40.33 Billion KRW | -484.152% |
| Whan In Pharm Co.,Ltd. | 632.02 Million KRW | -37183.52% |
| Dongwha Pharm.Co.,Ltd | 48.25 Billion KRW | -388.322% |
| Boryung Corporation | 204.21 Billion KRW | -15.388% |
| Bukwang Pharmaceutical Co., Ltd. | 79.38 Billion KRW | -196.826% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | -176.705% |
| JW Lifescience Corporation | 46.31 Billion KRW | -408.804% |